C:\documents and settings\administrator\my documents\giannini\notes&memos\questionnaire.wpd
LAW OFFICES OF PATRICK E. CATALANO A PROFESSIONAL CORPORATION SAN DIEGO OFFICE SAN FRANCISCO OFFICE The Koll Center 781 Beach Street, Suite 333 501 West Broadway, Suite 740 San Francisco, California 94109 San Diego, California 92101-3544 (415) 788-0207 (619) 233-3565 Fax: (415) 447-0066 Fax: (619) 233-9841 Charles S. LiMandri, Esq. Nicholas A. Siciliano, Esq. LAW OFFICES OF CHARLES S. LiMANDRI LAW OFFICES OF MASRY & VITITOE P.O. Box 9120 A Professional Corporation 16236 San Dieguito Road 5707 Corsa Avenue, Second Floor Building 3, Suite 3-15 Westlake Village, California 91362 Rancho Santa Fe, California 92067 (818) 991-8900 (858) 759-9930 Fax: (818) 991-6200 Fax: (858) 759-9938 CLIENT QUESTIONNAIRE Ann Giannini, et. al. v. Schering-Plough, et. al.
Client Name:______________________________________________________________
Date of diagnosis of Hepatitis C:__________________________________________
Genotype:____________________________________________________________
Viral Load (if known):__________________________________________________
Severity and type of Hepatitis C symptoms (mild, moderate, severe) prior totreatment:__________________________________________________________
_________________________________________________________________________
Other medical conditions at the time of diagnosis:___________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
Who suggested PEG-Intron and/or Rebetol treatment?_________________________
_________________________________________________________________________
Was Schering-Plough the manufacturer of the PEG-Intron and/or Rebetolused?______________________________________________________________
Client QuestionnairePage 2_______________________
Did your physician describe the potential risks and benefits of this therapy?
say?_____________________________________________
_________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
Did your physician describe the types of serious reactions you might experience?
If yes, what were these adverse reactions?___________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
Date PEG-Intron and/or Rebetol therapy started:______________________________
Where was the PEG-Intron and/or Rebetol obtained? Please state the name, addressand telephone number of the pharmacy:____________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
___________________________________________________________________________
Do you have any paperwork regarding the order of PEG-Intron and/or Rebetol? Ifyes, please attach.
Were you told to wait to begin therapy until a new form of Intron was available fortreatment?__________________________________________________________
If yes, how long did you wait?__________________________________________
__________________________________________________________________________
Date PEG-Intron and/or Rebetol therapy stopped:_____________________________
Was Rebetol (ribavirin) also prescribed and if so what was the dosage?___________
__________________________________________________________________________
Client QuestionnairePage 3_______________________
Please list other medications taken at the same time:___________________________
__________________________________________________________________________
__________________________________________________________________________
Dat e o f f i r s t a d v e r s e re a c t i on t o PEG- I n t ron and/or Rebetol:____________________________________________________________
How long were you treated before your adverse reactions started?_______________
__________________________________________________________________________
___________________________________________________________________________
Please list the adverse reactions and note their severity:________________________
__________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
__________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_________________________________________________________________________
Do you still have these adverse reactions?__________________________________
__________________________________________________________________________
Have these adverse reactions become less or more severe?______________________
__________________________________________________________________________
Are these adverse reactions disabling?_____________________________________
_________________________________________________________________________
Were you hospitalized because of these adverse reactions?_____________________
__________________________________________________________________________
Client QuestionnairePage 4_______________________
Why do you think PEG-Intron and/or Rebetol caused these symptoms?____________
__________________________________________________________________________
___________________________________________________________________________
_________________________________________________________________________
___________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
Did your physician adjust your dose or discontinue treatment after you reported thesesymptoms to him/her?___________________________________________________
__________________________________________________________________________
Did you report the adverse reactions(s) to the drug company and, if so, which drugcompany (name, address, telephone number)?________________________________
__________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
If yes, how did the drug company respond?__________________________________
___________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
Did you report the adverse reaction(s) to the FDA or to anyone else and, if so, pleaselist in detail:__________________________________________________________
__________________________________________________________________________
___________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
__________________________________________________________________________
Client QuestionnairePage 5_______________________
Do you know the lot numbers of any of the PEG-Intron and/or Rebetol or ribavirintreatments you took and, if so, please list:__________________________________
_________________________________________________________________________
_________________________________________________________________________
How did you obtain your Intron or PEG-Intron and/or Rebetoldrug?_______________________________________________________
_________________________________________________________________________
___________________________________________________________________________
Identify by batch and lot number the PEG-Intron and/or Rebetolused?______________________________________________________________
__________________________________________________________________________
1) Nakazato K, Kim C, Terajima K, Murata S1), Fujitani H, Nakanishi K, Tajima H1), Kumazaki T1),Sakamoto A(1)Department of Radiology/Center for Advanced Medical Technology, Nippon Medical School):Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvicperfusion. Journal of Cancer Research and Clinical Oncology2) Akada S, Fagerlund MJ1), Lindahl SG
CONVENTION INTERNATIONALE CONTRE LE DOPAGE DANS LE SPORT Annexe I - Liste des interdictions - Standard international LISTE DES INTERDICTIONS 2011 CODE MONDIAL ANTIDOPAGE Entrée en vigueur le 1er janvier 2011 Toutes les substances interdites doivent être considérées comme des « substances spécifiées » sauf les substances dans les classes S1, S2.1 à S2.5, S4.4 e